ImmuCell Corp Files 8-K on Financials
Ticker: ICCC · Form: 8-K · Filed: Oct 8, 2024 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, results-of-operations
Related Tickers: ICEL
TL;DR
ImmuCell dropped an 8-K detailing its financial condition and results. Check it for the latest numbers.
AI Summary
ImmuCell Corporation filed an 8-K on October 8, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing pertains to the company's ongoing business operations and financial reporting requirements.
Why It Matters
This filing provides an update on ImmuCell's financial health and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- October 8, 2024 (date) — Date of earliest event reported
- 56 Evergreen Drive Portland, Maine 04103 (address) — Principal executive offices
- 207-878-2770 (phone_number) — Registrant's telephone number
FAQ
What is the purpose of this Form 8-K filing?
The Form 8-K is being filed to report on ImmuCell Corporation's results of operations and financial condition, and to file financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 8, 2024.
What is ImmuCell Corporation's principal executive office address?
ImmuCell Corporation's principal executive office is located at 56 Evergreen Drive, Portland, Maine 04103.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is 207-878-2770.
What is the company's state of incorporation?
The company's state of incorporation is Delaware (DE).
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-10-08 16:05:10
Key Financial Figures
- $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The NASDAQ
Filing Documents
- ea0217094-8k_immu.htm (8-K) — 26KB
- ea021709401ex99-1_immu.htm (EX-99.1) — 19KB
- 0001213900-24-086275.txt ( ) — 219KB
- iccc-20241008.xsd (EX-101.SCH) — 3KB
- iccc-20241008_lab.xml (EX-101.LAB) — 33KB
- iccc-20241008_pre.xml (EX-101.PRE) — 22KB
- ea0217094-8k_immu_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On October 8, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its preliminary, unaudited product sales for the three-month and nine-month periods ended September 30, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated October 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: October 8, 2024 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of ImmuCell Corporation dated October 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3